News Quiz: Diabetes and Endocrinology Hot Topics in 2015

December 22, 2015

It has been an eventful year in the field of diabetes and endocrinology, from the US approval at the start of the year for recombinant parathyroid hormone (Natpara, NPS Pharmaceuticals) as an adjunct to calcium and vitamin D to control hypocalcemia in patients with the rare endocrine disorder of hypoparathyroidism, to the landmark results of the EMPA-REG trial in a group of patients with one of the most prevalent conditions on the planet — type 2 diabetes with coexisting cardiovascular disease.

Medscape has charted all of these advances; see how well you remember what happened in 2015.

Landmark EMPA-REG Trial Results

In September, doctors at the European Association for the Study of Diabetes (EASD) meeting in Stockholm gave the presenters of the EMPA-REG study a standing ovation, as they reported that the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim/Lilly) was the first-ever agent for type 2 diabetes to reduce mortality in a cardiovascular outcomes study.